| Bid | 7.54 |
| Market Cap | 516.66M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.99 |
| PE Ratio (ttm) | -3.8 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.59 |
| Volume | 119,001 |
| Avg. Volume (20D) | 982,463 |
| Open | 7.60 |
| Previous Close | 7.20 |
| Day's Range | 7.23 - 7.65 |
| 52-Week Range | 6.90 - 30.99 |
| Beta | undefined |
About EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting...
Analyst Forecast
According to 8 analyst ratings, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 283.09% from the latest price.
Next Earnings Release
Analysts project revenue of $11.02M, reflecting a -21.44% YoY shrinking and earnings per share of -0.48, making a 45.45% increase YoY.
2 months ago · seekingalpha.com
EyePoint Pharmaceuticals: Low Price And Good Data Create An OpportunityEyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety...
